Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roginolisib and Ruxolitinib in Myelofibrosis Unresponsive to JAK Inhibitors
NCT06887803Phase 2Recruiting
- Sponsor
- iOnctura
- Start
- Nov 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of roginolisib in myelofibrosis (MF), sponsored by iOnctura. Primary endpoints: Treatment Emergent Adverse Events, Abnormal ECG recordings and 2 more. Started Nov 2025; status: recruiting.
02
Drugs
roginolisib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06887803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06887803.